Antibody Information

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

ARB102-IR700 [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 36.97% (Day 21)	High CDH17 expression (CDH17 +++)
Method Description	The tumor-bearing mice were subjected to three cycles of PIT treatment, once per week.
In Vivo Model	SNU-C1 CDX model
In Vitro Model	Colon adenocarcinoma	SNU-C1 cells		CVCL_1708
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.92% (Day 21)	High CDH17 expression (CDH17 +++)
Method Description	The tumor-bearing mice were subjected to three cycles of PIT treatment, once per week.
In Vivo Model	LoVo CDX model
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.65% (Day 28)	High CDH17 expression (CDH17 +++)
Method Description	The tumor-bearing mice were subjected to three cycles of PIT treatment, once per week.
In Vivo Model	AsPC-1 CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 58.37% (Day 21)	High CDH17 expression (CDH17 +++)
Method Description	The tumor-bearing mice were subjected to three cycles of PIT treatment, once per week.
In Vivo Model	AsPC-1 CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Revealed Based on the Cell Line Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.12 ug/mL	High CDH17 expression (CDH17 +++)
Method Description	GI cancer cells were treated with PIT and cell viability was measured by MTT assay to determine EC50. Data is presented as mean SEM (n=3).
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	49.00 ng/mL	High CDH17 expression (CDH17 +++)
Method Description	GI cancer cells were treated with PIT and cell viability was measured by MTT assay to determine EC50. Data is presented as mean SEM (n=3).
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	74.00 ng/mL	High CDH17 expression (CDH17 +++)
Method Description	GI cancer cells were treated with PIT and cell viability was measured by MTT assay to determine EC50. Data is presented as mean SEM (n=3).
In Vitro Model	Colon adenocarcinoma	SNU-C1 cells		CVCL_1708
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	86.00 ng/mL	High CDH17 expression (CDH17 +++)
Method Description	GI cancer cells were treated with PIT and cell viability was measured by MTT assay to determine EC50. Data is presented as mean SEM (n=3).
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

References

Ref 1	Cadherin-17 Targeted Near-Infrared Photoimmunotherapy for Treatment of Gastrointestinal Cancer. Mol Pharm. 2020 Oct 5;17(10):3941-3951. doi: 10.1021/acs.molpharmaceut.0c00700. Epub 2020 Sep 24.